Skip to content
Back to Blog
Bio
2025-11-129 min read50

Cell and Gene Therapy Development Trends and Outlook

Current trends and future prospects in cell and gene therapy (CGT) development, including key technological advances and market opportunities.

KITIM Consulting Team

Cell and Gene Therapy Development Trends and Outlook

Cell and gene therapy (CGT) represents one of the most transformative areas of modern medicine, offering the potential for curative treatments for previously intractable diseases. The field has experienced explosive growth, with approved products demonstrating remarkable clinical outcomes and an expanding pipeline promising further breakthroughs. This guide examines current trends and future directions.

CGT Market Overview

  • CAR-T cell therapy: Chimeric Antigen Receptor T-cell therapy has become the flagship CGT modality, with multiple approved products for hematologic malignancies and expanding exploration into solid tumors
  • Gene editing: CRISPR-Cas9 and next-generation gene editing tools are advancing from research applications toward clinical therapies, with the first CRISPR-based therapy receiving regulatory approval
  • iPSC therapies: Induced pluripotent stem cell-derived therapies are emerging as a promising platform for generating off-the-shelf cell therapy products
  • Global market projections: The global CGT market is expected to exceed USD 40 billion by 2030, with growth driven by expanding indications and improved manufacturing
  • Pipeline expansion: Over 2,000 CGT clinical trials are active globally, representing a broad range of therapeutic areas beyond oncology
  • Technology Platforms

    Key technology platforms driving CGT development include:

  • Viral vectors: Adeno-associated virus (AAV) and lentiviral vectors remain the dominant delivery platforms for gene therapy and CAR-T manufacturing, respectively
  • CRISPR gene editing: CRISPR-Cas9 and newer variants (base editors, prime editors) enable precise genome modification, with applications in both ex vivo and in vivo gene therapy
  • Ex vivo approaches: Patient cells are collected, modified outside the body, and reinfused. This approach dominates current CGT products but faces scalability challenges
  • In vivo approaches: Direct delivery of genetic material to target tissues within the patient's body, eliminating the need for cell collection and processing
  • mRNA-based therapies: Building on COVID-19 vaccine technology, mRNA platforms are being explored for protein replacement therapy and in situ CAR-T generation
  • Non-viral delivery: Lipid nanoparticles, polymer-based systems, and other non-viral delivery methods are being developed as alternatives to viral vectors
  • Manufacturing Challenges

    CGT manufacturing presents unique complexities compared to traditional pharmaceuticals:

  • Autologous vs. allogeneic: Autologous products (derived from individual patients) require patient-specific manufacturing, creating logistic and economic challenges. Allogeneic (donor-derived) products offer off-the-shelf potential but face immunological hurdles
  • Scalability: Scaling CGT manufacturing from clinical to commercial volumes requires significant process development, particularly for viral vector production
  • Cost reduction: Current CGT manufacturing costs are extremely high, with some products priced above USD 400,000 per treatment. Process innovations and platform technologies are needed to reduce costs
  • Quality control: CGT products require extensive characterization and potency testing, with limited shelf life and complex release specifications
  • Supply chain: Ensuring timely delivery of living cell products from manufacturing facilities to clinical sites requires specialized cold chain logistics
  • Regulatory Landscape

  • MFDS advanced therapy framework: Korea's MFDS has established a regulatory framework for advanced therapy products, including expedited review pathways for regenerative medicine products
  • Global harmonization: Regulatory authorities worldwide are working toward harmonized standards for CGT evaluation, though significant differences remain between regions
  • Accelerated pathways: Most major regulatory agencies offer accelerated approval pathways for CGT products addressing serious or life-threatening conditions
  • Post-market monitoring: Given the novel nature of CGT products, regulatory authorities require extensive long-term follow-up, typically 15 years for gene therapy products
  • Manufacturing standards: GMP requirements for CGT are evolving, with specific guidelines for cell-based products, viral vector production, and gene editing processes
  • Korean CGT Ecosystem

    Korea has developed a growing CGT ecosystem with several competitive advantages:

  • Key companies: Korean companies including Curocell, GC Cell, and Toolgen are advancing CGT programs across multiple therapeutic areas
  • Government initiatives: The Korean government has designated CGT as a strategic growth area, providing dedicated R&D funding, regulatory support, and infrastructure investment
  • Academic research: Leading Korean universities and research institutes are conducting cutting-edge CGT research, creating a pipeline of innovations and trained researchers
  • Manufacturing infrastructure: Korea is investing in CGT manufacturing facilities, including GMP-grade viral vector production and cell processing centers
  • Regulatory incentives: MFDS offers priority review, conditional approval, and other incentives for CGT products addressing unmet medical needs
  • How KITIM Can Help

    KITIM supports CGT companies with government R&D funding applications, regulatory strategy consulting, manufacturing facility planning, and business development support. Our team stays current with the rapidly evolving CGT landscape to provide relevant, actionable guidance. Contact us to discuss your CGT development program.

    Cell TherapyGene TherapyCGT

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.